ES2181298T3 - Analogos de tiroxina que poseen una actividad hormonal no significativa para el tratamiento de tumores malignos. - Google Patents
Analogos de tiroxina que poseen una actividad hormonal no significativa para el tratamiento de tumores malignos.Info
- Publication number
- ES2181298T3 ES2181298T3 ES98955056T ES98955056T ES2181298T3 ES 2181298 T3 ES2181298 T3 ES 2181298T3 ES 98955056 T ES98955056 T ES 98955056T ES 98955056 T ES98955056 T ES 98955056T ES 2181298 T3 ES2181298 T3 ES 2181298T3
- Authority
- ES
- Spain
- Prior art keywords
- thyroxine
- tumors
- hormonal activity
- ketone
- evil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Utilización de un análogo de cetona tiroxina que tiene la fórmula siguiente para la preparación de un medicamento para el tratamiento de un tumor maligno sensible a los compuestos siguientes en un mamífero, presentando dicho análogo de cetona tiroxina una actividad hormonal significativa y siendo un compuesto capaz de inhibir la velocidad inicial del conjunto de la proteína microtubular in vitro: **fórmula** y sus sales farmacéuticamente aceptables, en la que: X = O, S, CH2, carboxi o ausente; Y = O ó S; R1 = metil ó etil; R2, R3, R4 y R5 se seleccionan independientemente de entre el grupo que consta de: H, alquil C1-C4, alquenil C1-C4, alquinil C1-C4, hidroxil, alcoxi C1-C4 y halógeno; R6, R7, R8 y R9 se seleccionan independientemente de entre el grupo que consta de: H, alquil C1-C4, alquenil C1-C4, alquinil C1-C4, hidroxil, alcoxi C1-C4, halógeno, NO2 y NH2; y R10 se selecciona de entre el grupo que consta de alquil C1-C4, alquenil C1-C4 y alquinil C1-C4.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/956,711 US5922775A (en) | 1997-10-23 | 1997-10-23 | Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2181298T3 true ES2181298T3 (es) | 2003-02-16 |
Family
ID=25498590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98955056T Expired - Lifetime ES2181298T3 (es) | 1997-10-23 | 1998-10-23 | Analogos de tiroxina que poseen una actividad hormonal no significativa para el tratamiento de tumores malignos. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5922775A (es) |
| EP (1) | EP1024800B1 (es) |
| AT (1) | ATE222489T1 (es) |
| AU (1) | AU1195499A (es) |
| DE (1) | DE69807349T2 (es) |
| ES (1) | ES2181298T3 (es) |
| WO (1) | WO1999020263A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6017958A (en) * | 1996-06-04 | 2000-01-25 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
| JP2002507567A (ja) * | 1998-03-25 | 2002-03-12 | ラージ スケール バイオロジー コーポレイション | 血管形成を阻害するための安息香酸誘導体 |
| US6433012B1 (en) * | 1998-03-25 | 2002-08-13 | Large Scale Biology Corp. | Method for inhibiting inflammatory disease |
| US6326402B1 (en) * | 1998-08-12 | 2001-12-04 | Octamer, Inc. | Methods for treating viral infections using a compound capable of inhibiting microtubules |
| US6638977B1 (en) | 1999-11-19 | 2003-10-28 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists |
| WO2001036351A2 (en) | 1999-11-19 | 2001-05-25 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
| US6613534B2 (en) | 2001-03-20 | 2003-09-02 | Wake Forest University Health Sciences | MAP-2 as a determinant of metastatic potential |
| CN1882327A (zh) * | 2003-11-19 | 2006-12-20 | 症变治疗公司 | 含磷的新的拟甲状腺素药 |
| CA2606499C (en) | 2005-05-26 | 2017-06-13 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
| MX2007014501A (es) * | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Tiromimeticos novedosos que contienen acido fosfinico. |
| KR20080035630A (ko) * | 2005-07-18 | 2008-04-23 | 바이파 사이언스 인코포레이티드 | 암의 치료 |
| US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| CA2655257A1 (en) * | 2006-06-12 | 2008-12-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| WO2008030892A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
| US8143447B2 (en) | 2006-09-05 | 2012-03-27 | Bipar Sciences, Inc. | Treatment of cancer |
| EP2061479A4 (en) * | 2006-09-05 | 2010-08-04 | Bipar Sciences Inc | FETTIC ACID SYNTHESIS INHIBITED BY PARP HEMMER AND TREATMENT PROCEDURES THEREWITH |
| AU2007292302A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Methods for designing PARP inhibitors and uses thereof |
| EP2211854A4 (en) * | 2007-10-19 | 2011-01-12 | Bipar Sciences Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS |
| KR20100102609A (ko) | 2007-11-12 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법 |
| AU2009212401A1 (en) * | 2008-02-04 | 2009-08-13 | Bipar Sciences, Inc. | Methods of diagnosing and treating PARP-mediated diseases |
| US10874641B2 (en) | 2016-07-28 | 2020-12-29 | Mitobridge, Inc. | Methods of treating acute kidney injury |
| RU2019114863A (ru) | 2016-11-02 | 2020-12-03 | Иммуноджен, Инк. | Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp |
| CA3044059A1 (en) | 2016-11-21 | 2018-05-24 | Viking Therapeutics, Inc. | Method of treating glycogen storage disease |
| BR112019016132A2 (pt) * | 2017-02-03 | 2020-04-07 | Univ California | composições e métodos para a inibição de reticulon 4 |
| BR112019025659A2 (pt) | 2017-06-05 | 2020-08-25 | Viking Therapeutics, Inc. | composições para o tratamento de fibrose |
| US11433074B2 (en) | 2017-06-22 | 2022-09-06 | Triact Therapeutics, Inc. | Methods of treating glioblastoma |
| EP3687501A4 (en) | 2017-09-29 | 2021-06-23 | Triact Therapeutics, Inc. | INIPARIB FORMS AND USES THEREOF |
| AU2019238090A1 (en) | 2018-03-22 | 2020-10-08 | Viking Therapeutics, Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| WO2019195658A1 (en) | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Sting levels as a biomarker for cancer immunotherapy |
| JP2021534214A (ja) * | 2018-08-24 | 2021-12-09 | ゼニオプロ ゲーエムベーハー | 抗増殖活性を有するフェノキシ（ヘテロ）アリールエーテル |
| WO2021041532A1 (en) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB643089A (en) * | 1947-10-23 | 1950-09-15 | Glaxo Lab Ltd | Improvements in or relating to the preparation of 2:6-dihalogeno diphenyl ethers |
| GB642159A (en) * | 1947-10-23 | 1950-08-30 | Glaxo Lab Ltd | Improvements in or relating to the preparation of diphenyl ethers |
| US4724234A (en) * | 1982-09-17 | 1988-02-09 | Therapeutical Systems Corp. | Method for producing oncolysis |
| US4816255A (en) * | 1985-07-31 | 1989-03-28 | Ghent William R | Treatment of iodine deficiency breast syndrome |
| GB9211415D0 (en) * | 1992-05-29 | 1992-07-15 | Ici Plc | Process for the production of purified terephthalic acid |
| US5736576A (en) * | 1996-06-04 | 1998-04-07 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
| US6017958A (en) * | 1996-06-04 | 2000-01-25 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
-
1997
- 1997-10-23 US US08/956,711 patent/US5922775A/en not_active Expired - Lifetime
-
1998
- 1998-10-23 ES ES98955056T patent/ES2181298T3/es not_active Expired - Lifetime
- 1998-10-23 DE DE69807349T patent/DE69807349T2/de not_active Expired - Lifetime
- 1998-10-23 WO PCT/US1998/022383 patent/WO1999020263A1/en active IP Right Grant
- 1998-10-23 AT AT98955056T patent/ATE222489T1/de active
- 1998-10-23 AU AU11954/99A patent/AU1195499A/en not_active Abandoned
- 1998-10-23 EP EP98955056A patent/EP1024800B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1024800A1 (en) | 2000-08-09 |
| ATE222489T1 (de) | 2002-09-15 |
| US5922775A (en) | 1999-07-13 |
| EP1024800B1 (en) | 2002-08-21 |
| WO1999020263A1 (en) | 1999-04-29 |
| DE69807349T2 (de) | 2003-01-02 |
| AU1195499A (en) | 1999-05-10 |
| DE69807349D1 (de) | 2002-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2181298T3 (es) | Analogos de tiroxina que poseen una actividad hormonal no significativa para el tratamiento de tumores malignos. | |
| DK0954299T3 (da) | Thyroxin-analoger uden signifikant hormonal aktivitet til behandling af ondartede tumorer | |
| BR9715022A (pt) | Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada | |
| BR0112038A (pt) | Triazolopirimidinas substituìdas como agentes anticâncer | |
| ATE461698T1 (de) | Gaba-analoga zur verhütung und behandlung gastrointestinaler beschwerden | |
| ATE501722T1 (de) | Therapeutische behandlung androgenrezeptorbedingter leiden | |
| BRPI0207961B8 (pt) | uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
| CY1105501T1 (el) | Συνδυασμοι φαρμακων (π.χ. chlorpromazine και pentamidine) για την αντιμετωπιση νεοπλαστικων διαταραχων | |
| ES2148229T3 (es) | Eteres y tioeteres en la posicion 17 de 4-aza-esteroides. | |
| ATE347366T1 (de) | Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen | |
| ES2151467T1 (es) | Inhibicion de la actividad de la quinasa p38 por aril-ureas. | |
| DE69631478D1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
| ATE197670T1 (de) | Parenterales busulfan zur behandlung von malignen krankheiten | |
| ES2154693T3 (es) | Combinacion de sustancias inductoras de necrosis con sustancias que son activadas por necrosis, para la terapia selectiva de tumores y enfermedades inflamatorias. | |
| ATE311853T1 (de) | Verwendung von krillenzymen zur behandlung von zahnbelag | |
| DE69724682D1 (de) | Verwendung von Gonadotropin releasing Hormon Analogen oder änlichen Verbindungen zur Herstellung von pharmazeutischen Zubereitungen als Zusatz für invasiver Behandlung von Karzinomen | |
| ATE438618T1 (de) | Inhibitoren von humanem adam-10 | |
| NO932101L (no) | Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker | |
| ES2114615T3 (es) | Nueva sonda para el diagnostico de tumores o la terapia de tumores. | |
| SE9601395D0 (sv) | New therapeutic treatment 1 | |
| SE9601396D0 (sv) | New therapeutic treatment 2 | |
| PT100111A (pt) | Composicao para o tratamento de um mamifero sofrendo de doenca proliferativa dapele, benigna ou maligna, compreendendo um analogo de somatostatina | |
| WO2023164455A3 (en) | Compositions and methods to modulate the immune system | |
| ES2110057T3 (es) | Composicion medicinal que contiene tcf-ii. | |
| BR9908518A (pt) | Utilização do fator de crescimento de monócitos cd137 ou de um análogo funcional do mesmo, processos in vitro para promover a proliferação de monócitos periféricos, para o tratamento regenerativo de pacientes de quimioterapia ou de terapia com radiação, e para promover a defesa imunológica não-especìfica endógena, utilização de uma sequencia de nucleotìdeos que codifica para cd137 ou um análogo funcional do mesmo, composição de terapia de genes, e, processo de terapia de genes para o tratamento de um dos distúrbios |